Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alzheimer Disease
Trial enrollment completed for DURIN-based leuprolide product candidate
March 3rd, 2005
DURECT Corp. (DRRX), an emerging specialty-pharmaceutical systems company, and Voyager Pharmaceutical Corp., a privately held specialty-pharmaceutical company focused on diseases of aging, announced the completion of enrollment for the recently approved study for the DURIN-based leuprolide acetate product candidate for Alzheimer disease under development by the parties (the DURIN-leuprolide implant). The U.S. Food and Drug Administration (FDA) accepted Voyager's investigational new drug application and clinical protocol in late December, 2004, and this unique formulation is being used in the present study in healthy volunteers to evaluate the product candidate's...
Source: Women's Health Weekly (2005-03-03)
|
